ICYMI: 2021 Rheumatology Year in Review
Jul 08, 2022
For 2022, let's look our top 10 list of advances, game-changers, worries and those better medical practices that evolved during 2021.
Read Article
Proposed investigations (findings) in the diagnosis of Stills disease:
- CRP, ESR, Ferritin (high)
- W/U for infection, cancer (negative)
- Serologies (negative)
- consider Imaging (CXR, CT, US, PET)https://t.co/l3yqAx6PA0 https://t.co/Sg7okwKHaw
Links:
Dr. John Cush @RheumNow( View Tweet )
Jul 11, 2022
Video: Cancer after Biologic Use in Patients with a History of Prior Malignancyhttps://t.co/jr37Ti7c9J https://t.co/iYCXzhXD44
Links:
Dr. John Cush @RheumNow( View Tweet )
Jun 30, 2022
Watch: Cancer after Biologic Use in Patients with a History of Prior Malignancyhttps://t.co/46f4xsCj31 https://t.co/rr3EfgCSCF
Links:
Dr. John Cush @RheumNow( View Tweet )
Jun 08, 2022
Malignancy risk on b/tsDMARDs in patients with prior malignancy history
For autoimmune patients with a history of malignancy, the initiation of biologic or targeted synthetic disease modifying agents (bDMARD/tsDMARDs) may provoke concern.https://t.co/cZwJFoqx0C https://t.co/QgoN0Qd5yz
Links:
Dr. John Cush @RheumNow( View Tweet )
Jun 06, 2022
Malignancy risk on b/tsDMARDs in patients with prior malignancy history
Jun 04, 2022
For autoimmune patients with a history of malignancy, the initiation of biologic or targeted synthetic disease modifying agents (bDMARD/tsDMARDs) may provoke concern. While data for biologic medications and malignancy risk has been largely reassuring, clinical trials have often excluded
Read Article
Castrejon et al. BIOBADASER registry study. Cancer risk with various bDMARDs. Overall I don't think there is a difference here. Lowest in IL17i and highest in abatacept but older and comorbidity confounders @RheumNow #EULAR2022 #POS1439 https://t.co/gfv78ouOTJ
Richard Conway @RichardPAConway( View Tweet )
Jun 03, 2022
Padoan et al. Cancer increased in EGPA. SIR 1.99 (1.22-3.08) all cancer, 1.86 (0.98-2.75) exc. NMSC. Higher ANCA+ 2.42 (1.30-4.16) and CYC treated 2.42 (1.11-4.60). 60% within years 1-5 post diagnosis @RheumNow #EULAR2022 POS0838 https://t.co/9GDLsBknO6
Richard Conway @RichardPAConway( View Tweet )
Jun 03, 2022
Meudec et al. Comparative effects of JAKi on NK cell function on cancer cells (lymphoma and lung cancer). Tofacitinib had most negative impact. Interesting given blanket black box based on tofa data! @RheumNow #EULAR2022 OP0265 https://t.co/XSE7hP60Ui https://t.co/MjtAJcvWAD
Links:
Richard Conway @RichardPAConway( View Tweet )
Jun 03, 2022
🧫 JAKi and NK
cells activation:
JAKi and particularly TOFA impacts NK cells:
*phenotype
*function
*impairs the control of proliferation of lung cancer and lymphoma cell lines
An explanation for the increase of cancer events in ORAL surveillance?
@RheumNow #EULAR2022 OP0265 https://t.co/LzMLdzcsDU
Aurelie Najm @AurelieRheumo( View Tweet )
Jun 03, 2022
Dr Singh @NamrataRheum et al. VA study of lymphoma risk with b/tsDMARDs. No increased risk found. HR adjusted time-fixed and time-varying covariates vs csDMARD 1.04 (0.80-1.35) @RheumNow #EULAR2022 POS1434 https://t.co/B6ENz805yl
Richard Conway @RichardPAConway( View Tweet )
Jun 03, 2022
EULAR 2022 – Day 2 Report
Jun 02, 2022
A full day at EULAR with oral and poster presentations of abstracts in the morning and a plethora of scientific (review) sessions in the afternoon. The latter covering topics like sarcoidosis, Still’s disease, fibromyalgia, back pain, sarcopenia, APS, IgG4 and imaging in vasculitis.
Read Article
No significant difference in malignancy risk in patients with rheumatic disease and a prior history of malignancy, who started bDMARDs or tsDMARDs. Interestingly IL-17i had 0 malignancy events and CD-20i were next lowest.
@RheumNow #EULAR2022 ABST#OP0138 https://t.co/Mq3YvOrSY8
Robert B Chao, MD @doctorRBC( View Tweet )
Jun 02, 2022
Pascual et al. Anti-TIF1gamma and cancer risk in DM and non-DM. Cancer in 60% of DM and 21% of non-DM patients with Anti-TIF1gamma https://t.co/OxKdlmDBBD
Richard Conway @RichardPAConway( View Tweet )
Jun 02, 2022
BIOBADASER Registry data on comparative drug-dependent cancer risk in patients with prior cancer. 352 patients. 32 incident cancers (14 NMSC). No difference between agents, but wide CIs @RheumNow #EULAR2022 OP0138 https://t.co/NEZSL2AQhC https://t.co/EG0NflXXW6
Links:
Richard Conway @RichardPAConway( View Tweet )
Jun 02, 2022
Spanish safety registry BIOBADASER 3.0:
*9000+ pts with IMID treated w/ bio or tsDMARDS
*352 pts w/ prior malignancy
*32 incident malignancies
-> 27 events/1000PY
NO diff between ttmts in incidence or mortality but low number pts in non TNFi groups
@RheumNow #EULAR2022
OP0138 https://t.co/8IyC6NdGCF
Aurelie Najm @AurelieRheumo( View Tweet )
Jun 02, 2022
#EULAR2022 RA updated reccs w/ minor changes: start MTX+GC, reduce GC rapidly, JAKi are recc only for pts w/o risk factors for CV or malignant dz (not sure I agree with this last one if the JAKi is the best drug for the pt and there are little options avail) @rheumnow https://t.co/CXyyCi6LVI
TheDaoIndex @KDAO2011( View Tweet )
Jun 01, 2022
Immune Checkpoint Inhibitor Associated Arthritis
May 30, 2022
Immune checkpoint inhibitors (ICIs) have dramatically improved outcomes in numerous cancers but have been hampered by a growing spectrum of immune-related adverse events (irAEs). Rheumatic complaints may be less frequent than other irAEs associated with ICI in cancer patients.Â
Read Article
The Inflammation Reflex (5.20.2022)
May 20, 2022
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. This week, neuroimmunology leading to therapy, the cold shoulder approach and Regulatory updates from the FDA.
Read Article
Increased Cancer Risk with Autoimmune Disorders (AID)
The incidence and mortality of cancer among AID was studied in a large Chinese cohort, demonstrating that while onset time and risks vary, there is an increased risk of malignancy in AID.https://t.co/T2WkOWp0cA https://t.co/iNJioAvrIe
Links:
Dr. John Cush @RheumNow( View Tweet )
Apr 01, 2022
Increased Cancer Risk with Autoimmune Disorders
Mar 31, 2022
The incidence and mortality of cancer among autoimmune diseases (AID) was studied in a large Chinese cohort, demonstrating that while onset time and risks vary, there is an increased risk of malignancy in AID.
The cohort included 8,120 AID patients from a national tertiary referral
Read Article
IL-17i -
Good Long term safety profile and low malignancy risk
Best efficacy for nail psoriasis
@RheumNow #RNL2022 https://t.co/8T7wAGJChF
Robert B Chao, MD @doctorRBC( View Tweet )
Mar 20, 2022
Risk vs. Benefit Lessons from the ORAL Surveillance Study
Jan 27, 2022
In an editorial in the current edition of the NEJM, Dr. Jasvinder Singh comments on the Oral Surveillance trial (Ytterberg et al.), a 4-year randomized, open-label, noninferiority, postauthorization, safety end-point trial, in high risk active rheumatoid arthritis patients over age 50 years.
Read Article2021 Rheumatology Year in Review
Jan 08, 2022
Our top 10 list of advances, game-changers, worries and those better medical practices that evolved during 2021.
Read Article
Risk of Cancer w/ IgG4-related disease (IgG4-RD)? A meta-analysis of 10 studies shows compared to gen population, IgG4-RD has a higher risk of overall cancer(SIR 2.57), esp pancreatic (SIR 4.1) & lymphoma (SIR 69.2); but not lung or gastric cancer https://t.co/EzgMXIdFcL
Links:
Dr. John Cush @RheumNow( View Tweet )
Jan 06, 2022
Recent Blogs
The quality of the meeting was on par with the host city, with extensive data presented on a range of topics, from social media to drug safety. The organization committee did a great job and I got the feeling that most people felt the congress was user friendly given the magnitude of the event. During this year’s meeting, I had the privilege of working with the RheumNow team, which gave me the opportunity to hone my social media skills and get my Twitter game on. After reviewing plenty of posters and going to numerous presentations, here are my top take home messages as classified by disease state.
Read Post
